Healthcare Most Active: Pfizer (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Boston Scientific Corporation (NYSE:BSX)

Pfizer Inc. (NYSE:PFE) sued Torrent Pharmaceuticals Ltd. (TRP) in a bid to block sales of a generic version of erectile-dysfunction drug Viagra while the largest U.S. drug maker’s patent is still in effect. Pfizer Inc. (NYSE:PFE) shares after opening at $31.41 moved to $31.53 on last trade day and at the end of the day closed at $31.42. Company price to sales ratio in past twelve months was calculated as 4.15 and price to cash ratio as 6.61. Pfizer Inc. (NYSE:PFE) showed a negative weekly performance of -2.99%.

AIDS Healthcare Foundation (AHF), the largest global AIDS organization and a vocal critic of runaway drug pricing and drug profiteering, criticized Gilead Sciences, Inc. (NASDAQ:GILD), the leading HIV/AIDS drug maker, and its CEO John Martin for continuing their practice of pillaging U.S. taxpayers as a means to fund the company’s unbridled corporate gluttony. Gilead Sciences, Inc. (NASDAQ:GILD) shares advanced 0.53% in last trading session and ended the day on $75.45. Gilead Sciences, Inc. (NASDAQ:GILD) return on equity ratio is recorded as 28.30% and its return on assets is 13.70%. Gilead Sciences, Inc. (NASDAQ:GILD) yearly performance is 67.04%.

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved down -3.18% in last trading session and was closed at $7.91, while trading in range of $7.89 – $8.33. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date (YTD) performance is 15.98%.

After years of stagnating, its sales moribund and stock slinking along in single digits, there are new signs of life at the medical device maker Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) weekly performance is -3.57%. On last trading day company shares ended up $12.98. Boston Scientific Corporation (NYSE:BSX) distance from 50-day simple moving average (SMA50) is -1.09%. Analysts mean target price for the company is $13.81.